CDR202/BI 771716 is a highly specific antibody fragment of reduced size, enabling an optimized penetration through all retinal layers to the most critical target site driving geographic atrophy (GA) disease pathology.
CDR505 is a tumor-selective M-gager® targeting novel cancer testis antigen, KK-LC-1, on HLA-A*01. This target is highly prevalent in common cancers and relevant for a yet unaddressed HLA-A*01 patient population.
CDR813 is a differentiated M-gager® targeting PRAME with unparalleled potency and specificity. PRAME is a pan-cancer target expressed exclusively in cancer, and not normal tissue.
CDR404, our most advanced program, is a potent and tumor-selective M-gager® targeting the cancer testis antigen, MAGE-A4, an intracellular cancer specific antigen with expression in several frequent and difficult-to-treat solid tumors including lung, bladder and head and neck cancer.
CDR111 is a T cell engager targeting two complementary B cell targets for highly effective B cell depletion with cure potential in multiple autoimmune diseases.